73 related articles for article (PubMed ID: 24671679)
1. HSV-1 amplicon vectors as genetic vaccines.
Laimbacher AS; Fraefel C
Methods Mol Biol; 2014; 1144():99-115. PubMed ID: 24671679
[TBL] [Abstract][Full Text] [Related]
2. HSV-1 Amplicon Vectors as Genetic Vaccines.
Meier AF; Laimbacher AS
Methods Mol Biol; 2020; 2060():111-130. PubMed ID: 31617175
[TBL] [Abstract][Full Text] [Related]
3. HSV-1 amplicon vectors that direct the in situ production of foot-and-mouth disease virus antigens in mammalian cells can be used for genetic immunization.
D'Antuono A; Laimbacher AS; La Torre J; Tribulatti V; Romanutti C; Zamorano P; Quattrocchi V; Schraner EM; Ackermann M; Fraefel C; Mattion N
Vaccine; 2010 Oct; 28(46):7363-72. PubMed ID: 20851082
[TBL] [Abstract][Full Text] [Related]
4. HSV-1 amplicon vectors launch the production of heterologous rotavirus-like particles and induce rotavirus-specific immune responses in mice.
Laimbacher AS; Esteban LE; Castello AA; Abdusetir Cerfoglio JC; Argüelles MH; Glikmann G; D'Antuono A; Mattion N; Berois M; Arbiza J; Hilbe M; Schraner EM; Seyffert M; Dresch C; Epstein AL; Ackermann M; Fraefel C
Mol Ther; 2012 Sep; 20(9):1810-20. PubMed ID: 22713696
[TBL] [Abstract][Full Text] [Related]
5. Polycistronic Herpesvirus Amplicon Vectors for Veterinary Vaccine Development.
Meier AF; Laimbacher AS; Ackermann M
Methods Mol Biol; 2016; 1349():201-24. PubMed ID: 26458838
[TBL] [Abstract][Full Text] [Related]
6. Transfer of Anti-Rotavirus Antibodies during Pregnancy and in Milk Following Maternal Vaccination with a Herpes Simplex Virus Type-1 Amplicon Vector.
Meier AF; Suter M; Schraner EM; Humbel BM; Tobler K; Ackermann M; Laimbacher AS
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212334
[TBL] [Abstract][Full Text] [Related]
7. Construction and packaging of herpes simplex virus/adeno-associated virus (HSV/AAV) Hybrid amplicon vectors.
Saydam O; Glauser DL; Fraefel C
Cold Spring Harb Protoc; 2012 Mar; 2012(3):352-6. PubMed ID: 22383640
[TBL] [Abstract][Full Text] [Related]
8. Herpes simplex virus type 1 (HSV-1)-derived amplicon vectors.
Melendez ME; Fraefel C; Epstein AL
Methods Mol Biol; 2014; 1144():81-98. PubMed ID: 24671678
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the immunogenicity of a recombinant HSV-1 vector expressing human group C rotavirus VP6 protein.
Rota RP; Palacios CA; Temprana CF; Argüelles MH; Mandile MG; Mattion N; Laimbacher AS; Fraefel C; Castello AA; Glikmann G
J Virol Methods; 2018 Jun; 256():24-31. PubMed ID: 29496429
[TBL] [Abstract][Full Text] [Related]
10. Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response.
Moraes MP; Segundo FD; Dias CC; Pena L; Grubman MJ
Vaccine; 2011 Nov; 29(51):9431-40. PubMed ID: 22027486
[TBL] [Abstract][Full Text] [Related]
11. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO
J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
Zibert A; Thomassen A; Müller L; Nguyen L; Glouchkova L; Fraefel C; Roskrow M; Meisel R; Dilloo D
Gene Ther; 2005 Dec; 12(23):1707-17. PubMed ID: 16034459
[TBL] [Abstract][Full Text] [Related]
13. A recombinant fusion protein and DNA vaccines against foot-and-mouth disease virus type Asia 1 infection in guinea pigs.
Zhang Q; Zhu MW; Yang YQ; Shao M; Zhang ZY; Lan HY; Yan WY; Wu JJ; Zheng ZX
Acta Virol; 2003; 47(4):237-43. PubMed ID: 15068379
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
15. Comparison of immune responses to different foot-and-mouth disease genetically engineered vaccines in guinea pigs.
Yao Q; Qian P; Huang Q; Cao Y; Chen H
J Virol Methods; 2008 Jan; 147(1):143-50. PubMed ID: 17963851
[TBL] [Abstract][Full Text] [Related]
16. Time-dependent biodistribution and transgene expression of a recombinant human adenovirus serotype 5-luciferase vector as a surrogate for rAd5-FMDV vaccines in cattle.
Montiel NA; Smoliga G; Arzt J
Vet Immunol Immunopathol; 2013 Jan; 151(1-2):37-48. PubMed ID: 23219159
[TBL] [Abstract][Full Text] [Related]
17. Early detection and visualization of human adenovirus serotype 5-viral vectors carrying foot-and-mouth disease virus or luciferase transgenes in cell lines and bovine tissues.
Montiel N; Smoliga G; Arzt J
Vaccine; 2012 Feb; 30(9):1690-701. PubMed ID: 22227230
[TBL] [Abstract][Full Text] [Related]
18. Increased transcomplementation properties of plasmids carrying HSV-1 origin of replication and packaging signals.
Berthomme H; Fournel S; Epstein AL
Virology; 1996 Feb; 216(2):437-43. PubMed ID: 8607275
[TBL] [Abstract][Full Text] [Related]
19. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
Da Costa XJ; Morrison LA; Knipe DM
Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
